Product name Orlistat tablets (Leli)
The main raw material is orlistat. Excipients include: microcrystalline cellulose, sodium starch glycolate, polyvinylpyrrolidone, sodium lauryl sulfate and talc. Its chemical name is: (S)-2-formylamino-4-methyl-pentanoic acid-(S)-1- { [(2S,3S)-3-hexyl-4-oxo-oxetan Methyl]dodecyl ester.
Main role for the treatment of obese or overweight patients (body mass index ≥ 24).
Product specifications 0.12g*1s*24 board (Leli)
Dosage Adults: The recommended dose is one serving (or orlistar) during the meal or within one hour after the meal. If there is a meal that does not enter or the food does not contain fat, you can omit the medication once.

[Adverse reactions] 1. Common adverse reactions are: oily spots, increased gastrointestinal exhaust, stool emergency, fat (oil) stool, steatorrhea, increased stool frequency and fecal incontinence. As the fat content of the diet increases, the incidence increases accordingly. Most patients can improve after a period of medication. 2. More frequently occurring gastrointestinal acute reactions include: abdominal pain/abdominal discomfort, flatulence, watery stools, soft stools, rectal pain/rectal discomfort, dental discomfort, and gum discomfort. 3. Other rare adverse events observed were: upper respiratory tract infection, lower respiratory tract infection, influenza, headache, menstrual disorders, anxiety, fatigue, and urinary tract infections. 4. Occasionally reported allergic to this product. The main clinical manifestations are itching, rash, urticaria, angioedema, bronchospasm and allergic reactions. 5. Case reports of herpes simplex, elevated liver transaminases and alkaline phosphatase, and rare severe hepatitis are rare.
[taboo] 1. Pregnant women are banned. 2. It is contraindicated in patients who are allergic to any of the ingredients in orlistat or pharmaceutical preparations. 3. Patients with chronic malabsorption syndrome and cholestasis are banned. 4. Organic obese patients (such as hypothyroidism) are banned.
Notes 1. Consult a physician before using the drug for the first time. You should go to the hospital regularly during the treatment. In particular, patients with hyperlipidemia, hypertension, diabetes, and moderate to severe fatty liver should be treated with other drugs under the guidance of a physician. 2. This drug is not recommended for people with a body mass index below 24. The approximate body mass index is calculated as weight/height 2 (weight in kilograms and height in meters). 3. When taking this medicine, try to reduce the intake of foods with high fat content. 4. The use of this drug should also pay attention to the combination of exercise and control diet in order to achieve good results. 5. There is no evidence that the drug can increase the effect after increasing the dosage. Therefore, please take the recommended dosage and do not increase the dosage. 6. It is recommended to take Orlistat no more than 3 times a day. 7. Children under the age of 18 and lactating women should not use the drug. 8. Those who are allergic to the drug are banned, and allergies are used with caution. 9. It is forbidden to use when the trait of the drug changes. 10. Keep the medicine out of the reach of children. 11. If you are using other medicines, please consult your physician or pharmacist before using this medicine. 12. Due to the rare acute liver hepatocyte necrosis or severe liver injury after the onset of orlistat, some cases require liver transplantation or can directly lead to death, so the prescription doctor should guide the patient to take the initiative to report the use of Orlist He developed any signs and symptoms of liver dysfunction (such as loss of appetite, itching, jaundice, dark urine, light stool, and pain in the right upper quadrant). When any of the above symptoms occur, orlistat and other suspicious drugs should be discontinued immediately and liver function tested. 13. Orlistat may increase the risk of urinary crystallization in the patient. Patients with a risk of renal insufficiency should monitor renal function during the course of taking orlistat. Patients with a history of high oxalic acid and calcium oxalate nephrolidity take Orlistis. He should be cautious.
[Children's medication] There are no relevant research results.
[medication in elderly patients] There are no relevant research results.
[Pregnant women and lactating women] Pregnant women are banned.
[drug interaction] 1. The drug reduces the absorption of vitamins A, D and E. The drug can be supplemented at the same time. If you are taking a preparation containing vitamins A, D, and E (such as some combination vitamins), take it 2 hours after taking the medicine or before going to bed. Patients with type 2 diabetes may need to reduce the dose of oral hypoglycemic agents (such as sulfonylureas). 3. When the drug is combined with cyclosporine, the plasma concentration of the latter is lowered. 4. When the drug is combined with amiodarone, it may cause a decrease in absorption of the latter and a decrease in efficacy. 5. If drug interactions may occur with other drugs, please consult your physician or pharmacist for details.
[Drug overdose] There are no relevant research results.
[Pharmacology and Toxicology] Orlistat is a reversible gastrointestinal lipase inhibitor that inactivates enzymes by forming covalent bonds with the active serine sites of gastric and intestinal lipase and pancreatic lipase. Enzymes do not hydrolyze fats (mainly triglycerides) in foods into absorbable free fatty acids and monoacylglycerols. Undigested triglycerides are not absorbed by the body, reducing calorie intake and controlling body weight. The drug does not need to be absorbed through systemic absorption. Orlistat can inhibit the absorption of 30% fat in food at a recommended therapeutic dose of 0.12 g three times a day. The drug does not need to be absorbed through the body to exert its effects, does not enter the blood, and produces intestinal adverse reactions that do not affect health. And most of the adverse reactions occur after a long-term use of drugs, the incidence is significantly reduced.
[Pharmacokinetics] Absorption: Studies of normal-weight and obese volunteers showed minimal absorption of orlistat in the body, and no complete plasma concentration of orlistat was measured 8 hours after oral administration (<5ng/ mL). The usual therapeutic dose of orlistat is extremely limited in systemic absorption, no accumulation, and only intact orlistat can be detected in plasma at very low concentrations (<10 ng/mL or 0.02 μm). Distribution: Since orlistat is hardly absorbed, it is difficult to measure its volume of distribution, and systemic pharmacokinetics cannot be detected. In vitro, more than 99% of orlistat binds to plasma proteins (lipoproteins, albumin are the major binding proteins). Orlistat rarely binds to red blood cells. Metabolism: Animal experiments suggest that the metabolism of orlistat is mainly concentrated in the gastrointestinal wall. Studies conducted in obese patients have shown that there are two major metabolites in the drug components that are rarely absorbed by the whole body, M1 (4-cyclo lactone hydrolysate) and M3 (M1 attached to an N-formyl bright The lysine cleavage product) accounted for 42% of the total plasma concentration. M1 and M3 have an open b-lactone ring that is very weak against lipase (1000-fold and 2500-fold lower than orlistat, respectively). At therapeutic doses, the inhibitory activities and plasma concentrations of M1 and M3 were very low (mean M1-26 μg/mL and M3-108 μg/mL), so these two metabolites were not of pharmacological significance. Clearance: Studies of normal weight and obesity have shown that unabsorbed drugs are excreted primarily through feces. Approximately 97% of the dose taken is excreted from the feces, 83% of which is prototypical orlistat, and the cumulative renal excretion of all related to orlistat is less than 2%. It takes 3-5 days for the drug to be completely discharged (feces and urine). For normal weight and obese subjects, the metabolism of orlistat is very similar. Orlistat, M1 and M3 can all be excreted via bile. Determination of the fat content in the stool indicates that the efficacy of the drug can be manifested 24-48 hours after administration, and the fat content in the stool is restored to the pre-treatment level 48-72 hours after the treatment is stopped.
[Storage] Sealed and stored.
[Package] 0.12g*1 piece*24 board/box.
[Validity] 24 months